The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia. Orna Therapeutics (through its wholly owned ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...

Here's why they think Eli Lilly (NYSE: LLY), Intuitive Surgical (NASDAQ: ISRG), and Vertex Pharmaceuticals (NASDAQ: VRTX) are unstoppable stocks to buy in 2025. David Jagielski (Eli Lilly): It may ...

NEW YORK, NY / ACCESSWIRE / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX ...

KING OF PRUSSIA, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, was recognized on Built In ...

Vertex has just filed for approval of Kalydeco for CF patients aged 18 and older who have the R117H mutation, the most common residual function mutation, which could add another 300 patients to ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbar radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

2/- to Re. 1/-. 13-Jun-22 10 2 Stock split from Rs. 10/- to Rs. 2/-. Darshan Orna Limited is an India-based integrated wholesaler of Jewelry and Ornaments. The Company is also into the trading ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex has appointed a new commercial head for ex-US activites, as the company aims to resolve its two-year row with UK health officials over the price of its cystic fibrosis drugs.